Home Tags Ado-trastuzumab emtansine

Tag: ado-trastuzumab emtansine

A Call to Action: Submit Your Expertise

Valuable lessons learned from both approved antibody-drug conjugates  (brentuximab vedotin /Adcetris®; Seattle Genetics approved in 2011 and ado-trastuzumab emtansine or T-DM-1/Kadcyla® approved in 2013)...

Phase I Study Shows Daichi Sankyo’s Anti-HER2 Antibody-drug Conjugate DS-8201a to...

Safety and preliminary efficacy data from a phase I study of DS-8201a (Daiichi Sankyo Company), a novel investigational HER2-targeting antibody drug conjugate or ADC,...

Anti-HER2 ADC SYD985 to be Evaluated in Expanded Cohort of HER2+...

Dutch pharmaceutical company Synthon Biopharmaceuticals has initiated the second part of an ongoing phase I clinical trial with its investigational anti-HER2 antibody-drug conjugate or ADC,...

Clinical Updates Confirming Advances and Meaningful Benefits for Patients

Earlier this year, during the meetings of the American Association for Cancer Research (AACR), held April 16-20 in New Orleans, LA, and the Protein...

Growing Drug Development Outsourcing Expected to Increase Demand for Antibody-drug Conjugates

A recent research report published by Technavio, a leading global technology research and advisory company, confirms that the global antibody-drug conjugates (ADC) market will grow...

Presurgery Combination of Trastuzumab Emtansine + Pertuzumab May Improve Outcomes of...

The I-SPY 2 TRIAL, a private-public partnership combining personalized medicine with a novel investigational design, is a neoadjuvant Phase II clinical trial screening agents in combination with...

Synaffix’s New High Potency Lab now Fully Operational to Support Growing...

Late last week, Synaffix, a Dutch biotechnology company backed by a top tier, life science-focused, investor syndicate and the strategic corporate venture capital fund of...

Survival Benefit of Ado-trastuzumab Emtansine in Heavily Pretreated HER2+ Breast Cancer...

Study results from the phase III TH3RESA clinical trial presented during the 38th San Antonio Breast Cancer Symposium (SABCS) held in San Antonio in December...

Biparatopic HER2-targeting Antibody-drug Conjugate Demonstrates Potent Antitumor Activity

HER2-targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer.  Being overexposed in 20-25% of human breast cancers...

Ado-trastuzumab Emtansine Fails Phase II/III GATSBY trial

Earlier today, in a short statement to the U.S. Securities Exchange Commission (SEC), ImmunoGen, Inc. disclosed that the Phase II/III Gatsby trial, a clinical...

X